Asthma  Most common chronic illness of childhood, affecting approximately 10% children.  Available preventive therapies for persistent asthma include.

Slides:



Advertisements
Similar presentations
HOW DO DRUGS GET INTO THE BODY?. WHY BE CONCERNED ABOUT HOW DRUGS GET INTO BODY? Bioavailability - % of dose that gets into body Bioequivalence - similarity.
Advertisements

Use of Medications in Asthma Cyril Grum, M.D. Department of Internal Medicine *Based on the University of Michigan Guidelines for Clinic Care and the National.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
In this study report the results of the effect of pH on the solubility of Nimesulide (BCS poorly soluble drug) in physiological pH. Some drugs having poor.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
IRON SUPPLEMENTATION Iron is an essential constituent of the body; necessary for hemoglobin formation and oxidative processes of living tissues. Iron deficiency.
CHAPTER 10 Basic Biopharmaceutics
Abwova Veronica Vugutsa B. Pharm
Drug Formulation in Pediatrics: If it tastes bad it must be good for you Jeffrey Blumer, Ph.D., M.D. Professor of Pediatrics and Pharmacology Case Western.
Ion-Exchange Resins as Drug Delivery Carriers Resins used are polymers that contain appropriately substituted acidic groups, such as carboxylic and sulfonic.
Dosage Form Design Murat Kizaibek. The Need for Dosage Forms.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Introduction A modification of the Fricke solution system to make it suitable for low-level dosimetric studies was proposed about three decades ago [1].
PHARMACEUTICS- IV (PHT 414 ) Dr. Shahid Jamil SALMAN BIN ABDUL AZIZ UNIVERSITY COLLEGE OF PHARMACY L /9/2015 Factors Affecting Drug Absorption (Dosage.
OBJECTIVES Based on the specific composition and manufacturing process, the modified release formulations have increased patient compliance, as well as.
A DONE BY: RONO KIPROTICH VICTOR U29/28970/2009 A COMPARATIVE STUDY ON DISSOLUTION PROFILES OF AMOXICILLIN IN AMOXICILLIN CONTAINING CAPSULES AVAILABLE.
1 Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July , 2008 Classification of Orally Disintegrating Tablets Frank O. Holcombe,
Quality control Lecture 1.
Formulation factors By Dr. A. S. Adebayo.
<701> DISINTEGRATION
SUPPOSITORIES - Definition - merits - limitations - formulations
1 Controlled drug release Dr Mohammad Issa. 2 Frequency of dosing and therapeutic index  Therapeutic index (TI) is described as the ratio of the maximum.
CHEE 4401 CAPSULES u solid dosage form u the drug is enclosed within either a hard or soft shell ä shell is typically made of gelatin u primarily intended.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
Introduction What is a Biowaiver?
Solid dosage forms Tablets
Lab 2. Assay of Aspirin using Back Titration Aspirin is a weak acid that also undergoes slow hydrolysis; i.e., each aspirin molecule reacts with two hydroxide.
Theophylline in broncial asthma. By:Heba Othman Essam El-Din Pharm –D4(2009).
Tablet Granulation. Introduction  Granulation is the process in which primary powder particles are made to adhere to form larger, multi particle entities.
Quality control Lecture 1.
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
Milling Is the reduction in the size mass by conversion of the large solid unit mass into smaller one by mechanical process. This needs energy.
Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate Ref.: European Journal of Pharmaceutics.
Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University
Physical Testing 1.Solutions 2.Disperse systems 3.Aerosols 4.Powders 5.Tablets 6.Sustained release products 7.Coated tablets 8.Hard & soft shell capsules.
content’s  Definition  Significance  Requirements of FDT  Formulation methodologies  Patented technologies  Potential candidates for FDT  Survey.
Comparative Bioavailability Study of a Novel Paediatric Tablets For Oral Suspension (TFOS) of Lamivudine, Nevirapine and Stavudine Vs Individual Reference.
- Pharmaceutical Equivalence Study
Results and Discussion
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
ASSESSMENT OF THE IMPACT OF HUMIDITY ON STABILITY OF APOTRIAVIR TABLETS AND ITS IMPLICATION IN BETTER TASTE RELEASE TRACPlus 2010 KIGALI, November 11,
Solid dosage forms Tablets
,Branko Vranic1, Nada Tarek2 ,V. Frost 3, G. Betz1
Dosage forms of drugs.
Biopharmaceutics factors affecting Modified release products
Controlled drug release
IPSA (Industrial Problem Solving Ability )
Systemic Procaterol (Meptin) as a CONTROLLER for Asthma
Factors Affecting Drug Absorption (Dosage form factor)
Quality control Lecture 1.
J.Preethi*, P. Madhu, K. Arshad Ahmed Khan.
Lab -7- Capsules.
Tablet Dosage Form Lab 1.
Drug Delivery Systems Pharmaceutical technology Petra University.
LAB.2 Tablet Production Methods
Lab 3 Industrial pharmacy
Nonsteroidal antiasthma agents
Lab -7- Capsules.
Aram I. Ibrahim University of sulaimani College of pharmacy
Biopharmaceutics 4th year
Pediatric Formulation Development - A quality perspective
Tablets Lecturer: dr. Asmaa abdelaziz Mohamed Faculty of pharamcay
Suppositories Aram I. Ibrahim.
Quality control Lecture 1.
Formulation factors By Dr. A. S. Adebayo.
University of sulaimani
Tablets.
Use of a Modified Sodium Bicarbonate and Lubricant Choice to Improve the Dissolution Rate of Weakly Acidic Drugs Michael S. Todd, Greg Simon, Stephen.
Fenofibrate USP (Micronized, control)
Presentation transcript:

Asthma  Most common chronic illness of childhood, affecting approximately 10% children.  Available preventive therapies for persistent asthma include inhaled delivery system containing corticosteroids and long acting beta agonists.  Adherence with inhaled therapies is poor in pediatrics.  Orally active leukotriene receptor antagonists are shown to be effective in pediatric patients.

Montelukast sodium  Indications: Prophylaxis and treatment of asthma, exercise induced asthma, in Aspirin sensitive asthamatics.  Potent, selective and orally acting leukotriene receptor antagonist.  Acts by inhibiting physiological actions of LTC4, LTD4 and LTE4 at the Cystiene Leukotriene levels (Cys LT1 receptor).  Dose: Adults :- 10 mg ODChild 6-14 yrs:- 5 mg OD 2-5 yrs :- 4 mg OD  Rapid oral absorption with mean oral bioavailability of 64 %.

Objective of incevtigation  Formulation palatable mouth dissolve tablets of Montelukast Sodium.  Evaluate the efficacy of Ion exchange resin (Indion 414) as superdisintegrant over the extsting ones in mouth dissolve tablets.

Melt in Mouth Tablets These are solid dosage forms that dissolve or disintegrate within a Minute in the oral cavity without the need of water or chewing and have a pleasant taste. Advantages offered  Ease of swallowing  Ease of handling  Improved patient compliance  Line extension and lifecycle management.

Ion Exchange Resins  Safe for oral consumption.  Indion 414 is a water insoluble, chemically crosslinked acrylic copolymer matrix with carboxylic acid as functional group (Potassium form).  Swelling property of ion exchange resins makes them ideal candidate as superdisintegrants.

Analytical Method Development UV Spectrophotometric method for analysis of Montelukast Sodium Detection max342 nm Linearity range10-50  g/ml Slope ± SD ± Regression coefficient0.999

Formulation Development  Montelukast Sodium was mixed in geometric proportions with superdisintegrants, sweetners, diluent, flavors and lubricants. Various concentrations of superdisintegrants were employed to arrive at an optimum disintegration time.  Blend was screened through 40 #.  Compressed on Cadmach single station tablet press machine equipped with 9 mm flat beveled punches.

Formulation details of melt in mouth tablets of Montelukast Sodium The tablet weight was fixed to 150 mg. Montelukast SodiumActive AspartameSweetner Avicel PH102Diluent Indion 414Superdisintegrant MentholCoolant Instacoat Strawberry flavorFlavor Supplied by Ideal Cures Pvt Ltd. TalcLubricant Magnesium stearateAnti adherent AerosilGlidant

Comparison of Indion 414 with existing superdisintegrants Superdisintegrants Appearance of tablet In-vitro disintegration time (sec) Indion 414Smooth20 Sodium Starch GlycolateSmooth15 Croscarmellose sodiumSmooth15 CrospovidonePitted10

Evaluation of the Optimized Formulation ParameterObservation AppearanceFlat beveled tablets off white in color TextureSmooth TastePalatable Dimensions9 mm in diameter Weight variation (mg) ± SD150 ± 2.87 Hardness (kg/cm 2 )3-4 In-vitro disintegration time (sec)20 Drug content (%)101.2% ± 1.34 Drug release (%) Apparatus – USP Type II Medium – 500 ml Water95% rpm – 100, Time – 30 min

Conclusion  Patient compliant and palatable melt in mouth tablets of Montelukast Sodium having optimum physicochemical properties were formulated.  Ion exchange resin (Indion 414) could be successfully used as superdisintegrant, thus making the formulation cost effective.  The tablets exhibited an in-vitro disintegration time of 20 seconds.  The technology can also be easily employed for large-scale manufacturing.

Acknowledgements The authors thank  Ideal Cures Pvt. Ltd. for providing financial assistance towards this presentation and also for gift samples of Instacoat flavors.  Cipla Ltd, Mumbai for gift sample of Montelukast Sodium.  Ion Exchange India Ltd for gift sample of Ion Exchange resin.